Ratio Therapeutics, Inc.

Biopharma merger and acquisition value for the fourth quarter of 2024 reached $9.4bn from 34 transactions, 15 of which had disclosed values. At the top was H. Lundbeck’s $2.6bn purchase of publicly tr

As Novartis management headed to London to meet investors and analysts after upping mid-term sales guidance, CEO Vas Narasimhan has been trumpeting the Swiss major’s pipeline and recent product launch

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Sarepta Obtains Rights To Seven Arrowh

Recent deals in radiopharmaceuticals, the latest being AstraZeneca PLC ’s acquisition of Fusion Therapeutics, have drawn investor attention to a modality that has been the focus of academic interest